Core Viewpoint - BioPorto A/S has appointed Klaus Juhl Wulff as the new Executive Vice President and Chief Financial Officer, effective May 1, 2026, highlighting the company's commitment to strengthening its management team for anticipated growth [1][2][3]. Company Overview - BioPorto is an in vitro diagnostics company focused on improving patient management through actionable biomarkers, aiming to address significant unmet medical needs [4]. - The company specializes in developing products that enhance clinical and economic outcomes for patients and healthcare providers [4]. Key Products - BioPorto's flagship products utilize the NGAL biomarker to assist in the risk assessment and diagnosis of Acute Kidney Injury (AKI), which can lead to severe health consequences if not treated promptly [5]. - The NGAL tests allow for quicker identification of patients at risk of AKI compared to standard care measurements, facilitating earlier interventions [5]. Leadership Appointment - Klaus Juhl Wulff brings over 20 years of experience in finance, operations, M&A, and capital markets, previously serving as CFO at AquaPorin A/S [2]. - The CEO of BioPorto, Carsten Buhl, expressed confidence in Wulff's ability to contribute strategically, particularly in supply chain management to support the company's growth trajectory [3].

February 5, 2026Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update                                                                         COPENHAGEN, DENMARK, February 5, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), today announced Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a business update.                                          A strong quar ...

February 5, 2026Announcement no. 1 BioPorto provides Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a Business Update COPENHAGEN, DENMARK, February 5, 2026, (GLOBE NEWSWIRE) – BioPorto A/S CVR-no. 17500317 (BioPorto or Company) (CPH:BIOPOR), today announced Preliminary Unaudited 2025 Financial Figures, Financial Guidance for 2026 and a business update. A strong quarter to close out the year - Preliminary Financial Figures for the Fourth Quarter of 2025 and Fiscal Year 2025 I ...

Group 1 - The Nipah virus outbreak in West Bengal, India has confirmed 5 cases with nearly 100 people under observation, prompting neighboring countries like Thailand and Nepal to enhance health screening for travelers from India [1] - The World Health Organization (WHO) classifies the Nipah virus as a high-priority regional threat due to its high mortality rate of 40%-70% and the absence of approved vaccines or treatments [4][11] - The research team from Wuhan Institute of Virology has published findings indicating that the oral nucleoside drug VV116 shows significant antiviral activity against the Nipah virus, providing new hope for treatment [2][8] Group 2 - VV116, developed by Wangshan Wangshui and Junshi Biosciences, has shown potential against various RNA viruses, including the Nipah virus, and has been approved for COVID-19 treatment in China and Uzbekistan [7][8] - Following the announcement of VV116's efficacy against the Nipah virus, shares of Wangshan Wangshui surged by 10.9%, reaching a new high since its listing in November 2025 [4][5] - The market response to the Nipah virus outbreak has led to significant stock price increases for several companies involved in diagnostic testing, with companies like Kaipu Biological and Da'an Gene reporting substantial gains [12][13]

Core Viewpoint - BioPorto A/S announced the resignation of CFO Niels Høy Nielsen, who will continue in his role until March 2026, as he transitions to a new position at another company [1][2]. Company Overview - BioPorto is an in vitro diagnostics company focused on improving patient management through actionable biomarkers, particularly in areas with significant unmet medical needs [4]. - The company utilizes its expertise in antibodies and assay development to create innovative products aimed at enhancing clinical and economic outcomes for patients and healthcare providers [4]. Key Products - BioPorto's flagship products are based on the NGAL biomarker, which aids in the risk assessment and diagnosis of Acute Kidney Injury (AKI) [5]. - The NGAL tests allow for quicker identification of patients at risk of AKI compared to standard care measurements, facilitating earlier intervention and tailored management strategies [5]. Company Operations - BioPorto operates facilities in Copenhagen, Denmark, and Boston, MA, USA, and is listed on the Nasdaq Copenhagen stock exchange [6].

Core Points - BioPorto A/S has completed a private placement of 40,438,426 new shares, raising approximately DKK 43 million in new capital [1][2] - The new shares represent 8.89% of BioPorto's registered share capital prior to the increase [2] - The nominal share capital of BioPorto now amounts to DKK 495,108,887, consisting of 495,108,887 shares [4] Company Overview - BioPorto is an in vitro diagnostics company focused on improving patient outcomes through actionable kidney biomarkers, particularly for Acute Kidney Injury (AKI) [5] - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and management of AKI, enabling earlier intervention [5] - BioPorto's tests are marketed under various registrations, including CE mark in several countries and FDA clearance for ProNephro AKI™ in the US [5] Trading and Listing - The new shares will be admitted to trading and officially listed on Nasdaq Copenhagen A/S under the company's permanent ISIN code [3] - The new shares carry the same rights as existing shares, including the right to receive dividends from the time the capital increase is registered [3] Capital Structure - Following the capital increase, BioPorto's Articles of Association have been updated to reflect the new share capital structure [4] - The company emphasizes its commitment to transparency and provides access to its announcements and relevant information through its investor relations platform [4]

Core Insights - BioPorto A/S has successfully completed a private placement, raising approximately DKK 43 million through the issuance of 40,438,426 new shares, which represents 8.89% of the company's registered share capital prior to the increase [1][2]. Group 1: Share Capital Increase - The capital increase has been registered with the Danish Business Authority, and the gross proceeds from the issue amount to approximately DKK 43 million [2]. - The new shares will carry the same rights as existing shares, including the right to receive dividends from the time the capital increase is registered [3]. Group 2: Company Overview - BioPorto is focused on in vitro diagnostics, particularly in developing kidney biomarkers to aid in the management of Acute Kidney Injury (AKI) [5]. - The company's flagship products utilize the NGAL biomarker, which allows for quicker identification of patients at risk of AKI, facilitating earlier intervention [5]. - BioPorto's shares are listed on the Nasdaq Copenhagen stock exchange, and the company has facilities in both Copenhagen, Denmark, and Boston, MA, USA [6].

Core Viewpoint - BioPorto A/S reported continued growth in NGAL sales and outlined strategic milestones in its "Forward" strategy aimed at transforming kidney care globally [1][5]. Financial Performance - Revenue for Q3 2025 reached DKK 10.4 million, a 7% increase year-over-year, and a 10% increase at constant exchange rates [9]. - Total revenue for the first nine months of 2025 was DKK 28.7 million, reflecting a 1% increase compared to the same period last year, with a 2% increase at constant exchange rates [9][10]. - NGAL sales in Q3 2025 totaled DKK 7.2 million, growing by 5% globally and 10% at constant exchange rates [9]. - For the first nine months of 2025, NGAL sales rose by 5% compared to the same period in 2024, and by 7% at constant exchange rates [10]. Strategic Developments - The company successfully delivered its first ProNephro AKI (NGAL) order to the US market in August 2025, marking a significant step in its commercial launch [8]. - Patient enrollment for the clinical cut-off study was completed by the end of October 2025, with a focus on thorough data analysis to ensure high-quality validation study design [4][8]. - The FDA submission has been postponed to the first half of 2027 to align with the updated study design based on FDA feedback [4][8]. Capital and Funding - On November 13, 2025, BioPorto completed a share issuance, raising approximately DKK 43 million, which is expected to support operations through 2026 [6][8]. - The company aims to achieve positive cash flow in the second half of 2027 [6]. Future Guidance - The full-year guidance for 2025 remains unchanged, with total revenue expected to be in the range of DKK 40-45 million and an Adjusted EBITDA loss projected between DKK 75-80 million [11][16].

Core Viewpoint - BioPorto A/S has successfully completed a private placement of 40,438,426 new shares, raising approximately DKK 43 million, which will enhance the company's financial flexibility to pursue strategic priorities and strengthen its commercial platform [1][2]. Group 1: Private Placement Details - The private placement involved 40,438,426 new shares and is expected to generate gross proceeds of around DKK 43 million [1][2]. - The subscription price for the new shares is scheduled to be paid by 24 November 2025, with the share capital increase registration to follow shortly thereafter [2]. - BioPorto anticipates that the new shares will be listed on Nasdaq Copenhagen A/S by no later than 26 November 2025 [2]. Group 2: Strategic Implications - The funds raised will support the completion of data collection, submission of a pre-submission to the FDA, and initiation of a Validation Study in the U.S. clinical trial [2]. - The Board of BioPorto has considered various future financing options, including potential divestments of non-core assets and credit facilities, to ensure a balanced funding structure [2]. - The company aims to position itself for positive cash flow by the second half of 2027 [2]. Group 3: Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable kidney biomarkers to improve patient management and outcomes [4][5]. - The flagship products are based on the NGAL biomarker, which aids in the risk assessment and management of Acute Kidney Injury (AKI) [5]. - BioPorto's tests are marketed under various registrations, including CE mark and FDA clearance for ProNephro AKI™ in the U.S. [5].

Core Viewpoint - BioPorto A/S has initiated a pre-subscribed private placement of up to 40,438,426 new shares to support its financing strategy aimed at achieving positive cash flow by the second half of 2027 [3][4][5]. Financing Strategy - The company identified a funding need of DKK 60–70 million to complete a U.S. clinical study and strengthen its commercial platform [4]. - A variety of financing alternatives were evaluated, including equity issuance and strategic financing solutions, to support long-term growth [4]. Private Placement Details - The private placement is fully pre-subscribed, with indications for the entire amount, expected to raise approximately DKK 43 million [5][9]. - The subscription price is set at DKK 1.072, matching the closing price of BioPorto shares on Nasdaq Copenhagen on the announcement date [9]. Share Offering Terms - The offering includes up to 40,438,426 new shares, representing 8.89% of the company's registered share capital prior to the increase [8]. - The new shares will carry the same rights as existing shares and will be registered through VP Securities A/S [10]. Timeline and Trading - The subscription period has commenced and will close at short notice, with results to be announced shortly thereafter [12]. - New shares are expected to be listed on Nasdaq Copenhagen by November 26, 2025, subject to the offering not being withdrawn [13]. Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable kidney biomarkers to improve patient management [15][16]. - The company's flagship products are based on the NGAL biomarker, aiding in the risk assessment and management of Acute Kidney Injury (AKI) [16].